Skip to Main Content

Paper Details

Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
Leukemia
44
2021
Author NameAffiliation
Farhad RavandiUniversity of Texas MD Anderson Cancer Center
Christopher S Houriganand Blood Institute, National Institutes of Health
  • 1 - 2

Datasets

Release 1.2